Can glucose-lowering drugs impact mortality in COVID-19 patients with type 2 diabetes?

October 30, 2020

CAMBRIDGE, MA - October 27, 2020-- In a
In their peer reviews of the study, Susanna Hofmann (Division Head, Helmholtz Diabetes Center) and Tamaryn Fox (Internal Medicine, Albert Einstein Medical Center) write in MIT Press Journal
Rapid Reviews: COVID-19 that the study is reliable, but would require further research. Their conclusion: "While this study is strong, drugs used during the hospital stay were not noted, making these conclusions hard to generalize."

Fox notes the need for this type of research: "There is a paucity of evidence concerning the impact of glucose-lowering drugs and their effect on those infected with COVID-19; thus, this study is relevant and brings insight to this ever-growing topic."

While Hofmann notes the study may be useful to point of care providers, writing, "Importantly, the authors report here valuable information how glucose-lowering drugs taken by [Type 2 Diabetes] patients at home affect hospital stay outcomes. This knowledge may come in very handy at hospital admission and for the treatment strategy during the hospital stay of these patients."

The RR:C19 Editorial Board highlights this research saying, "With Type 2 Diabetes being a known risk factor of COVID-19 and affecting millions worldwide, it is urgent to know whether the use of glucose lowering medications contributes to a patient's risk of mortality or ICU admission if they are diagnosed with COVID-19. In this study, administering commonly-administered drugs did not pose additional risk of ICU admission or hospital death as a result of COVID-19."


Impact of Glucose-Lowering Drugs on Mortality and Other Adverse Outcomes in Patients with Type 2 Diabetes Admitted for COVID-19

Pérez-Belmonte, Luis Miguel and Torres-Peña, José David and López-Carmona, María D. and Ayala-Gutiérrez, M. Mar and Fuentes-Jiménez, Francisco and Jorge Huerta, Lucía and Alonso Muñoz, Jaime and Rubio-Rivas, Manuel and Madrazo, Manel and Guzmán Garcia, Marcos and Vicente Montes, Beatriz and Fernández Sola, Joaquim and Ena, Javier and Gonzalez Ferrer, Ruth and Mella Pérez, Carmen and Ripper, Carlos J. and Napal Lecumberri, Jose Javier and El Attar Acedo, Iris and Plaza Canteli, Susana and Fuente Cosío, Sara and Amorós Martínez, Francisco and Cortés Rodríguez, Begoña and Pérez-Martínez, Pablo and Ramos-Rincón, José M. and Gómez-Huelgas, Ricardo and Group, SEMI-COVID-19 Network.

Find peer reviews and information about this study at Rapid Reviews website.Summary of reviews: Glucose-lowering medications have a neutral effect on mortality and adverse outcomes in those with Type 2 Diabetes hospitalized. While this study is strong, drugs used during the hospital stay were not noted, making these conclusions hard to generalize.

To learn more about this project and its editorial board, or to sign up for future news and alerts, visit
Rapid Reviews: COVID-19 is an open-access overlay journal that seeks to accelerate peer review of COVID-19-related research preprints. The journal is edited by Stefano M. Bertozzi, Professor of Health Policy and Management at the
Media Contacts

Jessica Pellien
Associate Director of Publicity
Fortier Public Relations

Kate Silverman Wilson
Community and Resource Development Associate
The MIT Press

The MIT Press

Related Cambridge Articles from Brightsurf:

Study suggests elderly care home outbreaks in England were caused by multiple indepedent infections and also within-home spread
New research presented at this week's ESCMID Congress on Coronavirus Disease (ECCVID, held online 23-25 September) shows that outbreaks of COVID-19 in elderly care homes were caused by multiple independent infections from outside, plus within care home spread.

One of Darwin's evolution theories finally proved by Cambridge researcher
Scientists have proved one of Charles Darwin's theories of evolution for the first time -- nearly 140 years after his death.

Inflammation in the brain linked to several forms of dementia
Inflammation in the brain may be more widely implicated in dementias than was previously thought, suggests new research from the University of Cambridge.

New score measuring multiple chronic illnesses performs better than current method
A new score that measures multiple long-term health conditions performs better than the current Charlson Comorbidity Index and may help in health care planning and delivery, according to new research in CMAJ (Canadian Medical Association Journal).

Online hate speech could be contained like a computer virus, say Cambridge researchers
Artificial intelligence is being developed that will allow advisory ''quarantining'' of hate speech in a manner akin to malware filters - offering users a way to control exposure to ''hateful content'' without resorting to censorship.

Admitting patterns of junior doctors may be behind 'weekend effect' in hospitals, study suggests
A study links the 'weekend effect' of increased hospital mortality to junior doctors admitting a lower proportion of healthy patients at the weekend compared to weekdays.

Electronic solid could reduce carbon emissions in fridges and air conditioners
A promising replacement for the toxic and flammable greenhouse gases that are used in most refrigerators and air conditioners has been identified by researchers from the University of Cambridge.

Cambridge scientists reverse aging process in rat brain stem cells
Scientists say the results have far reaching implications for how we understand the aging process, and how we might develop much-needed treatments for age-related brain diseases.

Hospital-acquired C. diff associated with substantial costs
A study by the Society for Healthcare Epidemiology of America determines the cost and length of stay attributed to hospital-acquired Clostridioides difficile infections.

Multiple concurrent central lines increases risk for bloodstream infection
A study by the Society for Healthcare Epidemiology of America demonstrates the relationship between multiple concurrent central lines and the increased risk for bloodstream infections.

Read More: Cambridge News and Cambridge Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to